Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Members of the human epidermal growth factor receptor (HER) family, which includes HER1
(also known as EGFR), HER2, HER3 and HER4, have played a central role in regulating cell …

Aptamers with high affinity and specificity for certain targets have rapidly become a novel
class of targeted ligands applicated in drug delivery. Based on the excellent characteristics …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Antibody-drug conjugates (ADCs) are rapidly establishing their place and have shown
promising preliminary data in lung cancer with impressive response rates and survival …

Drug conjugates, including antibody-drug conjugates, are a step toward realizing Paul
Ehrlich's idea from over 100 years ago of a “magic bullet” for cancer treatment. Through …

The development of new antitumor drugs depends mainly upon targeting tumor cells
precisely. Trophoblast surface antigen 2 (Trop-2) is a type I transmembrane glycoprotein …

Combining existing drug therapy is essential in developing new therapeutic agents in
disease prevention and treatment. In preclinical investigations, combined effect of certain …

Antibody-drug conjugates (ADCs) are a class of innovative biopharmaceutical drugs, which,
via their antibody (mAb) component, deliver and release their potent warhead (aka. payload) …